click below
click below
Normal Size Small Size show me how
Clinical Trials ACS
| Question | Answer |
|---|---|
| ISIS-2 | All reduce mortality ASA beneficial |
| ISG | Alteplace (tPA) More stroke and intracranial hemmorage, Streptokinase Increase bleed |
| ISIS-3 | Duteplace (tPA) increase in stroke, Heparin increase bleeding |
| Gusto | Alteplace(tPA) +streptokinase increase risk in bleed, Study flawed |
| Gusto III | Alteplace (tPA) and receteplace (rPA) not statistically different in mortality or stroke |
| Assent-2 | Tenecteplace (TNK) Fewer bleeding complications, less specificity, increase in intranial bleed and stroke. |
| Gusto V | Recelplace (rPA)+abciximab +heparin Increase risk for bleed |
| Assent-3 | Combination of lower dose, decrease mortality, reinfarct |
| EPIC | Abciximab 60% reduction in mortality, 13% 3 year reduction |
| EPILOG | Combo Abciximab+low dose weight LMWH adjusted decreases bleeding |
| PRISM | Alone Tirofiban increase mortality, Combo Tirofiban, heparin reduce in mortality |
| PURSUIT | All epitifibatide were significantly better than placebo |
| ESPIRIT | Eptifibatide + IIb/IIIa inhibitor decreases mortality risk 47% |
| Gusto-IV | Abciximab best with 24hour infusion |